AGP Executive Report
Last update: 5 hours agoFederal Oversight: The DEA has registered more than 900 state-licensed medical marijuana dispensaries in seven states under the new Schedule III framework. Patient eligibility and purchasing rules are unchanged, but registered operators must meet federal security and recordkeeping requirements. CBD and Hemp Policy: A federal hemp redefinition expected in December could reshape the market for hemp-derived CBD products. Safety and Research: The American Medical Association is urging FDA safety standards for cannabis and other botanical products. Separate reports link cannabis use with higher reported cardiovascular risk, especially stroke, and describe rising cases of cannabis hyperemesis syndrome; neither finding establishes a CBD-specific risk.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.